305.03
-5.91 (-1.90%)
| Previous Close | 310.94 |
| Open | 307.32 |
| Volume | 752,791 |
| Avg. Volume (3M) | 1,285,913 |
| Market Cap | 40,699,514,880 |
| Price / Earnings (TTM) | 130.91 |
| Price / Earnings (Forward) | 36.10 |
| Price / Sales | 11.56 |
| Price / Book | 53.58 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2026 |
| Profit Margin | -11.49% |
| Operating Margin (TTM) | 3.04% |
| Diluted EPS (TTM) | -2.11 |
| Quarterly Revenue Growth (YOY) | 20.20% |
| Total Debt/Equity (MRQ) | 2,358.25% |
| Current Ratio (MRQ) | 3.04 |
| Operating Cash Flow (TTM) | -45.11 M |
| Levered Free Cash Flow (TTM) | 223.09 M |
| Return on Assets (TTM) | -1.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Alnylam Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.25 |
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 3.81% |
| % Held by Institutions | 97.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 527.00 (Barclays, 72.77%) | Buy |
| Median | 445.50 (46.05%) | |
| Low | 408.00 (Morgan Stanley, 33.76%) | Hold |
| Average | 460.13 (50.85%) | |
| Total | 7 Buy, 1 Hold | |
| Avg. Price @ Call | 330.81 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 18 Feb 2026 | 510.00 (67.20%) | Buy | 332.68 |
| 30 Jan 2026 | 510.00 (67.20%) | Buy | 338.06 | |
| Canaccord Genuity | 17 Feb 2026 | 429.00 (40.64%) | Buy | 332.61 |
| Freedom Capital Markets | 17 Feb 2026 | 410.00 (34.41%) | Buy | 332.61 |
| Chardan Capital | 13 Feb 2026 | 425.00 (39.33%) | Buy | 314.40 |
| Needham | 12 Feb 2026 | 510.00 (67.20%) | Buy | 308.48 |
| B of A Securities | 30 Jan 2026 | 462.00 (51.46%) | Buy | 338.06 |
| Morgan Stanley | 30 Jan 2026 | 408.00 (33.76%) | Hold | 338.06 |
| Barclays | 28 Jan 2026 | 527.00 (72.77%) | Buy | 349.58 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Jan 2026 | Announcement | Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |